Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gubentongluo is a Traditional Chinese Medicine (TCM) preparation, typically administered as granules, developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is specifically formulated for the treatment of IgA nephropathy (IgAN) and chronic kidney disease. The name 'Gubentongluo' reflects its dual therapeutic mechanism: 'Guben' refers to strengthening the kidney's 'root' or foundation, while 'Tongluo' refers to unblocking the renal collaterals to promote blood circulation and resolve stasis. In clinical practice and research, it is often used as part of a staged treatment protocol that includes other TCM preparations like Astragalus Xiaobai and Yishen Zhishuang. The drug aims to reduce urinary protein levels, improve renal microcirculation, and mitigate the progression of glomerular sclerosis and interstitial fibrosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gubentongluo.